WS #15069
Biotech M&A activity is heating up as AstraZeneca invests $2 billion in Summit Therapeutics, validating the ivonescimab pipeline and providing crucial capital for development. In consumer discretionary, Carnival reported strong Q3 earnings, beating estimates and raising full-year guidance, indicating resilient consumer spending despite macro headwinds. IOVance also lifted its 2026 revenue guidance, reflecting strong demand for its cancer treatment Amtagvi.
Biotech M&A and Earnings
Biotech M&A activity is heating up as AstraZeneca invests $2 billion in Summit Therapeutics, validating the ivonescimab pipeline and providing crucial capital for development. In consumer discretionary, Carnival reported strong Q3 earnings, beating estimates and raising full-year guidance, indicating resilient consumer spending despite macro headwinds. IOVance also lifted its 2026 revenue guidance, reflecting strong demand for its cancer treatment Amtagvi.